The Food and Drug Administration issued an alert on August 27 identifying Medisca Inc. Lot 229536 as the common ingredient behind at least 30 adverse reactions reported by patients who received intravenous glutathione at wellness clinics and med spas. Federal investigators traced the contamination to a single supplier batch of dietary-supplement-grade powder that multiple independent compounding pharmacies used to prepare sterile injectable drips, as reported by Medical Daily.
The powder carried a printed caution reading "Dietary Supplement" and was manufactured at Medisca's U.S. headquarters in Plattsburgh, New York. FDA laboratory testing confirmed endotoxin levels in the material as high as five times the limit appropriate for the intravenous dose patients received, according to a follow-up compounding alert summarized by Medical Daily. The agency stated plainly that the ingredient should not have been used to compound sterile injectable drugs.
The alert lands at a moment when IV glutathione drips are marketed in English- and Spanish-language wellness content as a routine detoxification or "cellular reset" service, often at med spas and longevity clinics that do not hold pharmaceutical manufacturing licenses. Compounded drugs in the United States do not undergo premarket review for safety, effectiveness, or quality. No injectable glutathione product has received FDA approval. What remains unresolved is the full scope of exposure: the agency has not published a list of every compounding pharmacy that received Lot 229536, and it continues to receive new adverse-event reports.
Figure 1: A supply-chain trace showing how one dietary-grade glutathione supplier lot can enter multiple compounding pharmacies and emerge as separately labeled IV vials, leaving endotoxin traceability in the hands of the clinics.
From a Supplement Shelf to a Vein
The supply-chain failure the FDA described operates through a structural gap in how compounded injectables are sourced. A single lot of active pharmaceutical ingredient, or API, can be sold to dozens of compounding pharmacies, each of which then prepares its own finished product under its own label. In this case, every pharmacy implicated in the 30 reported reactions obtained its glutathione powder from the same Medisca lot, yet each pharmacy dispensed the resulting IV bags under a different name and lot number of its own choosing.
That structure means the recall responsibility falls on individual pharmacies rather than on a single manufacturer. Patients who received an infusion at a clinic in, say, Houston or Austin may have no way to determine whether their vial traced back to Lot 229536 unless the pharmacy voluntarily contacts them. The FDA's alert urges compounders who received dietary-supplement-grade glutathione from Medisca to notify their customers and instruct them to discontinue use of the IV product.
Endotoxin, the contaminant at the center of this alert, is a fragment of the outer membrane of certain bacteria. Swallowed in trace amounts, it passes through the digestive system with minimal effect. Injected directly into the bloodstream, it triggers a rapid immune cascade. The symptoms the FDA listed in its August 27 alert include fever, chills, pain, dizziness, muscle aches, headache, nausea, vomiting, low blood pressure, and signs consistent with sepsis or shock. Those reactions align with what clinicians have documented in prior cases of contaminated glutathione infusions, including a case series published in Epidemiology and Infection describing seven patients who developed probable endotoxin poisoning after receiving tainted IV glutathione at a complementary-medicine clinic.
For clinics that market IV drips as a low-risk wellness service, the distinction between oral and intravenous administration is the one that determines whether a contaminant causes mild stomach upset or a trip to the emergency room. Standard peptide testing protocols for injectable compounds include endotoxin assays, but those tests are the responsibility of the compounding pharmacy, not the ingredient supplier, and no federal premarket review mandates them before the product reaches a patient's arm.
Two Texas Recalls Before the Federal Trace
The August 27 alert did not arrive in isolation. On August 5, Victory Medical Center Pharmacy in Austin voluntarily recalled certain lots of its Compounded Glutathione 200 mg/mL Multi-Dose Vials after its own internal testing detected elevated bacterial endotoxin levels, according to the recall announcement published on the FDA's safety page. Patients reported fever, chills, severe headache, nausea, vomiting, rapid heartbeat, blood-pressure changes, body aches, and injection-site reactions.
Fourteen days later, Houston-based Optimal Balance Pharmacy recalled one lot of Compounded Glutathione 200 mg/mL 30 mL Multi-Dose Vials, lot LG342009076, distributed to patients in 14 states, as covered by Medical Daily. The company cited its own pharmacy testing as the trigger. Neither recall announcement disclosed whether the underlying powder originated from Medisca Lot 229536, and the FDA has not confirmed a direct supply link between those two pharmacy-level recalls and the supplier lot named in the August 27 alert.
The pattern drew attention beyond the clinic world. The International Association of Fire Fighters, representing roughly 360,000 first responders, issued a safety advisory warning members that glutathione given by IV or nebulizer is not an FDA-approved drug and that contamination at compounding facilities has caused documented poisonings, as reported by PBS NewsHour. The advisory followed reports that IV glutathione had been offered to wildland crews working the Spokane-area fires in August.
Medisca told the FDA on August 20 that it had sent its U.S. customers a warning not to use its dietary-supplement-grade glutathione to compound injectable drugs. That notification came one week before the agency's public alert. The FDA had previously communicated the same concern in 2019 and stated in its August 27 alert that it remains troubled by the continued use of dietary-grade material in sterile injectables.
An Open Case File
Federal investigators have not announced enforcement action against Medisca or any of the compounding pharmacies involved. The agency has not confirmed whether all 30 reported adverse events are confined to the two Texas pharmacies that issued recalls, nor has it indicated whether additional recalls will follow. The FDA's Pharmacy Compounding Advisory Committee has discussed adding glutathione to its list of ingredients subject to heightened compounding scrutiny, but no final rulemaking has been published.
Patients who received an IV glutathione infusion at a wellness clinic or med spa in recent months face a practical problem: the clinic, not the patient, holds the lot traceability record. The FDA's guidance directs healthcare professionals to contact their compounders and ask which source supplied the glutathione used in injectable preparations. Laboratories that perform hplc peptide testing on finished compounded products can detect endotoxin and verify identity, but those tests happen after the ingredient has already entered the vial, not before it enters the supply chain.
The agency says it is actively investigating and will publish updates as more information becomes available. As of August 28, the case count stands at "at least 30," a floor rather than a ceiling.
